← Back to Search

P2Y12 Inhibitor

HPR Group for Coronary Artery Disease (HEIGHTEN Trial)

Phase 4
Waitlist Available
Led By Paul A Gurbel, MD
Research Sponsored by LifeBridge Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 hour, 4 hour, 14 days
Awards & highlights

HEIGHTEN Trial Summary

The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who exhibit high-on prasugrel platelet reactivity defined as Vasodilator Stimulated Phosphoprotein-Phosphorylation (VASP-P) >50%.

Eligible Conditions
  • Coronary Artery Disease

HEIGHTEN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 hour, 4 hour, 14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 hour, 4 hour, 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacodynamic (PD) Vasodilator Stimulated Phosphoprotein-Phosphorylation(VASP-P) in High On Prasugrel Platelet Reactivity(HPPR) stable CAD patients
Secondary outcome measures
CYP2C19 relation to occurence of HPPR
Frequency of HPR
PD LTA in HPPR stable CAD patients
+3 more
Other outcome measures
Number of Participants with Adverse Events

HEIGHTEN Trial Design

2Treatment groups
Active Control
Group I: Non-HPR groupActive Control1 Intervention
The non-HPR group will have PD and genetic testing, with no change in medication.
Group II: HPR GroupActive Control2 Interventions
This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.

Find a Location

Who is running the clinical trial?

LifeBridge HealthLead Sponsor
28 Previous Clinical Trials
3,968 Total Patients Enrolled
8 Trials studying Coronary Artery Disease
2,367 Patients Enrolled for Coronary Artery Disease
AstraZenecaIndustry Sponsor
4,274 Previous Clinical Trials
288,613,021 Total Patients Enrolled
63 Trials studying Coronary Artery Disease
112,595 Patients Enrolled for Coronary Artery Disease
Paul A Gurbel, MDPrincipal InvestigatorLifeBridge Health
4 Previous Clinical Trials
335 Total Patients Enrolled
2 Trials studying Coronary Artery Disease
200 Patients Enrolled for Coronary Artery Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
2014. "Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01869309.
All > Brilinta
~35 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top